Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy

Cancer Immunology, Immunotherapy

Volumn 62, Issue 8, 2013, Pages 1283-1292

  Maletzki, Claudia ^a   Linnebacher, Michael ^a   Savai, Rajkumar ^b   Hobohm, Uwe ^c  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Cancer immunotherapy; Mistletoe extract; Mistletoe lectin; Pattern recognition receptor ligands; Shiga toxin

Indexed keywords

ANTINEOPLASTIC AGENT; FLAGELLIN; LIGAND; LIPOPOLYSACCHARIDE; MDP LIGAND; RESIQUIMOD; SHIGA TOXIN; TOLL LIKE RECEPTOR LIGAND; UNCLASSIFIED DRUG; VISCUM ALBUM LECTIN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER REGRESSION; CASE STUDY; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; IMMUNOGENICITY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SHIGELLA DYSENTERIAE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; FLAGELLIN; HUMANS; IMIDAZOLES; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MISTLETOE; MODELS, MOLECULAR; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PHYTOTHERAPY; PLANT LECTINS; PROTEIN CONFORMATION; SHIGA TOXIN; TIME FACTORS; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84880917245     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1455-1     Document Type: Review

References (89)

1. Hobohm U (2001) Fever and cancer in perspective. Cancer Immunol Immunother 50:391-396
2. Maletzki C, Linnebacher M, Kreikemeyer B, Emmrich J (2008) Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut 57:483-491. doi: 10.1136/gut.2007.125419
3. Zahl PH, Maehlen J, Welch HG (2008) The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 168:2311-2316. doi: 10.1001/archinte.168.21.2311
4. Deidier A (1725) Dissertation Medecinal et Chirurgical sur les Tumeurs, Paris
5. Rohdenburg G (1918) Fluctuations in the growth energy of malignant tumors in man, with especial reference to spontaneous recession. J Cancer Res 3:193-225
6. Pearl R (1929) Cancer and tuberculosis. Am J Hyg 9:97-162
7. Braunstein A (1929) Krebs und malaria. Z Krebsforsch 29:330-333
8. Braunstein A (1929) Experimentelle und klinische Grundlagen fuer Malariabehandlung des Krebses. Z Krebsforsch 29:468-490
9. Engel P (1934) Ueber den Infektionsindex der Krebskranken. Wien Klin Wochenschr 47:1118-1119
10. Sinek F (1936) Versuch einer statistischen Erfassung endogener Faktoren bei Carcinomerkrankungen. Z Krebsforsch 44:492-527
11. Diamond LK, Luhby LA (1951) Pattern of 'spontaneous' remissions in leukemia of the childhood, observed in 26 of 300 cases. Am J Med 10:238ff
12. West RO (1966) Epidemiologic study of malignancies of the ovaries. Cancer 19(7):1001-1007
13. Klyuyeva NG, Roskin GI (1963) Biotherapy of malignant tumours. Pergamon Press, Oxford
14. Kienle GS (2012) Fever in cancer treatment: Coley's therapy and epidemiological observations. Glob Adv Health Med 1(1):90-98
15. Witzel L (1970) History and other diseases in patients with malignant neoplasms. Med Klin 65(18):876-879
16. Stephenson HE Jr et al (1971) Host immunity and spontaneous regression of cancer evaluated by computerized data reduction study. Surg Gynecol Obstet 133(4):649-655
17. Zygiert Z (1971) Hodgkin's disease: remissions after measles. Lancet 1(7699):593
18. Ruckdeschel JC et al (1972) Postoperative empyema improves survival in lung cancer. documentation and analysis of a natural experiment. N Engl J Med 287(20):1013-1017
19. Newhouse ML et al (1977) A case control study of carcinoma of the ovary. Br J Prev Soc Med 31(3):148-153
20. Menczer J et al (1979) Possible role of mumps virus in the etiology of ovarian cancer. Cancer 43(4):1375-1379
21. Cramer DW et al (1983) Mumps, menarche, menopause, and ovarian cancer. Am J Obstet Gynecol 147(1):1-6
22. Remy W et al (1983) Tumorträger haben selten Infekte in der Anamnese. Med Klin 78:95-98
23. Ronne T (1985) Measles virus infection without rash in childhood is related to disease in adult life. Lancet 1(8419):1-5
24. Enterline PE et al (1985) Endotoxins, cotton dust, and cancer. Lancet 2(8461):934-935
25. van Steensel-Moll HA, Valkenburg HA, van Zanen GE (1986) Childhood leukemia and infectious diseases in the first year of life: a register-based case-control study. Am J Epidemiol 124(4):590-594
26. Grossarth-Maticek R et al (1987) Reported herpes-virus-infection, fever and cancer incidence in a prospective study. J Chronic Dis 40(10):967-976
27. Rotoli B et al (1982) Long-term survival in acute myelogenous leukemia complicated by chronic active hepatitis. N Engl J Med 307(27):1712-1713
28. Treon SP, Broitman SA (1992) Beneficial effects of post-transfusional hepatitis in acute myelogenous leukemia may be mediated by lipopolysaccharides, tumor necrosis factor alpha and interferon gamma. Leukemia 6(10):1036-1042
29. Abel U et al (1991) Common infections in the history of cancer patients and controls. J Cancer Res Clin Oncol 117(4):339-344
30. Mastrangelo G, Fadda E, Milan G (1998) Cancer increased after a reduction of infections in the first half of this century in Italy: etiologic and preventive implications. Eur J Epidemiol 14(8):749-754
31. Albonico HU, Braker HU, Husler J (1998) Febrile infectious childhood diseases in the history of cancer patients and matched controls. Med Hypotheses 51(4):315-320
32. Maurer S, Koelmel KF (1998) Spontaneous regression of advanced malignant melanoma. Onkologie 21:14-18
33. Schlehofer B et al (1999) Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer 82(2):155-160
34. Koelmel KF et al (1999) Infections and melanoma risk: results of a multicenter EORTC case study. Melanoma Res 9:511-519
35. Stewart BW, Kleihues P (2003) World Cancer report. World Health Organization, IARC Press, Lyon
36. Koelmel KF et al (2005) Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 41(1):118-125
37. Mastrangelo G et al (2005) Lung cancer risk: effect of dairy farming and the consequence of removing that occupational exposure. Am J Epidemiol 161(11):1037-1046
38. Jeys LM et al (2007) Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol 14(10):2887-2895
39. Kim SY et al (2008) The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease. Am J Hematol 83(10):784-788
40. Vestergaard H et al (2010) Tonsillitis, tonsillectomy and Hodgkin's lymphoma. Int J Cancer 127(3):633-637
41. Rudant J et al (2010) Childhood acute leukemia, early common infections, and allergy: the ESCALE Study. Am J Epidemiol 172(9):1015-1027
42. Urayama KY et al (2010) A meta-analysis of the association between day-care attendance and childhood acute lymphoblastic leukaemia. Int J Epidemiol 39(3):718-732
43. Urayama KY et al (2011) Early life exposure to infections and risk of childhood acute lymphoblastic leukemia. Int J Cancer 128(7):1632-1643
44. Rudant J et al (2011) Childhood Hodgkin's lymphoma, non-Hodgkin's lymphoma and factors related to the immune system: the Escale Study (SFCE). Int J Cancer 129(9):2236-2247
45. Chilvers C et al (1986) The common cold, allergy, and cancer. Br J Cancer 54(1):123-126
46. Cardwell CR et al (2008) Infections in early life and childhood leukaemia risk: a UK case-control study of general practitioner records. Br J Cancer 99(9):1529-1533
47. Hoffmann C et al (2002) Childhood diseases, infectious diseases, and fever as potential risk factors for cancer? Forsch Komplementarmed Klass Naturheilkd 9:324-330
48. Chen Y et al (1992) Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 21(1):23-29
49. Mantovani A, Pierotti MA (2008) Cancer and inflammation: a complex relationship. Cancer Lett 267:180-181
50. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436-444. doi: 10.1038/nature07205
51. Christian S, Palmer L (1928) An apparent recovery from multiple sarcoma with involvement of both bone and soft parts treated by toxin of erysipelas and bacillus prodigiosus. Am J Surg 43:188-197
52. Coley-Nauts HC, Fowler GAA, Bogatko FH (1953) A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man. Acta Med Scand 145:5-102
53. Hobohm U, Stanford JL, Grange JM (2008) Pathogen-associated molecular pattern in cancer immunotherapy. Crit Rev Immunol 28:95-107
54. Hobohm U (2009) Toward general prophylactic cancer vaccination. BioEssays 31:1071-1079. doi: 10.1002/bies.200900025
55. Molassiotis A, Fernadez-Ortega P, Pud D et al (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655-663. doi: 10.1093/annonc/mdi110
56. Kirsch A, Hajto T (2011) Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy. J Altern Complement Med 17:973-979. doi: 10.1089/acm.2010.0596
57. Ostermann T, Bussing A (2012) Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore (NY) 8:277-281. doi: 10.1016/j.explore.2012.06.005
58. Bussing A, Raak C, Ostermann T (2012) Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med. 2012:219402. doi: 10.1155/2012/219402
59. Kienle GS, Kiene H (2010) Review article: influence of Viscum album L. (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 9:142-157. doi: 10.1177/1534735410369673
60. Orange M, Fonseca M, Lace A, Laue HB, Geider S (2010) Durable tumour responses following primary high dose induction with mistletoe extracts: two case reports. Eur J Integr Med 2:63-69
61. Orange M, Lace A, Fonseca MP, Laue BH, Geider S, Kienle GS (2012) Durable regression of primary cutaneous B-cell lymphoma following fever-inducing mistletoe treatment: two case reports. Global Adv Health Med 1:18-25
62. Lee CH, Kim JK, Kim HY, Park SM, Lee SM (2009) Immunomodulating effects of Korean mistletoe lectin in vitro and in vivo. Int Immunopharmacol 9:1555-1561. doi: 10.1016/j.intimp.2009.09.011
63. Huber R, Ludtke H, Wieber J, Beckmann C (2011) Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters: a placebo controlled clinical trial in healthy subjects. BMC Complement Altern Med 11:116. doi: 10.1186/1472-6882-11-116
64. Thies A, Dautel P, Meyer A, Pfuller U, Schumacher U (2008) Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model. Br J Cancer 98:106-112. doi: 10.1038/sj.bjc.6604106
65. Ma YH, Cheng WZ, Gong F, Ma AL, Yu QW, Zhang JY, Hu CY, Chen XH, Zhang DQ (2008) Active Chinese mistletoe lectin-55 enhances colon cancer surveillance through regulating innate and adaptive immune responses. World J Gastroenterol 14:5274-5281
66. Park HJ, Hong JH, Kwon HJ, Kim Y, Lee KH, Kim JB, Song SK (2010) TLR4-mediated activation of mouse macrophages by Korean mistletoe lectin-C (KML-C). Biochem Biophys Res Commun 396:721-725. doi: 10.1016/j.bbrc.2010.04.169
67. Abagyan RA, Batalov S (1997) Do aligned sequences share the same fold? J Mol Biol 273:355-368
68. Peri F, Piazza M (2012) Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Biotechnol Adv 30:251-260. doi: 10.1016/j.biotechadv.2011.05.014
69. Biswas SK, Lopez-Collazo E (2009) Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30:475-487. doi: 10.1016/j.it.2009.07.009
70. Benwell RK, Lee DR (2010) Essential and synergistic roles of IL1 and IL6 in human Th17 differentiation directed by TLR ligand-activated dendritic cells. Clin Immunol 134:178-187. doi: 10.1016/j.clim.2009.09.013
71. Muthing J, Meisen I, Kniep B et al (2005) Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1- 4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J 19:103-105. doi: 10.1096/fj.04-2494fje
72. Branden C, Tooze J (1999) Introduction to protein structure. Garland Science, New York
73. Greene LH, Lewis TE, Addou S et al (2007) The CATH domain structure database: new protocols and classification levels give a more comprehensive resource for exploring evolution. Nucleic Acids Res 35:D291-D297. doi: 10.1093/nar/gkl959
74. Hobohm U (2005) Fever therapy revisited. Br J Cancer 92:421-425. doi: 10.1038/sj.bjc.6602386
75. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-174. doi: 10.1038/nri2506
76. Pawelek JM, Low KB, Bermudes D (2003) Bacteria as tumour-targeting vectors. Lancet Oncol 4:548-556
77. Gandhi NM, Morales A, Lamm DL (2013) Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU Int. doi: 10.1111/j.1464-410X.2012. 11754.x
78. Kimura NT, Taniguchi S, Aoki K, Baba T (1980) Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 40:2061-2068
79. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, Penman S, Hoffman RM (2005) Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 102:755-760. doi: 10.1073/pnas.0408422102
80. Zhao M, Yang M, Ma H, Li X, Tan X, Li S, Yang Z, Hoffman RM (2006) Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 66:7647-7652. doi: 10.1158/0008-5472.CAN-06-0716
81. Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Hoffman RM (2009) Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem 106:992-998. doi: 10.1002/jcb.22078
82. Kimura H, Zhang L, Zhao M, Hayashi K, Tsuchiya H, Tomita K, Bouvet M, Wessels J, Hoffman RM (2010) Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Prolif 43:41-48. doi: 10.1111/j.1365-2184.2009.00652.x
83. Liu F, Zhang L, Hoffman RM, Zhao M (2010) Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity. Cell Cycle 9:4518-4524
84. Momiyama M, Zhao M, Kimura H, Tran B, Chishima T, Bouvet M, Endo I, Hoffman RM (2012) Inhibition and eradication of human glioma with tumor-targeting Salmonella typhimurium in an orthotopic nude-mouse model. Cell Cycle 11:628-632. doi: 10.4161/cc.11.3.19116
85. Agrawal N, Bettegowda C, Cheong I et al (2004) Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci USA 101:15172-15177. doi: 10.1073/pnas.0406242101
86. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13:552-559. doi: 10.1038/nm1589
87. Krishnan J, Lee G, Choi S (2009) Drugs targeting Toll-like receptors. Arch Pharm Res 32:1485-1502. doi: 10.1007/s12272-009-2100-6
88. Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C (2012) Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 7:29-54. doi: 10.1007/s11523-012-0213-1
89. Zoglmeier C, Bauer H, Norenberg D et al (2011) CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 17:1765-1775. doi: 10.1158/1078-0432.CCR-10-2672